SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S ...

PITTSBURGH, April 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Letrozole Tablets USP, 2.5 mg, under a previously ...

These kinases are activated upon binding to D-cyclins and play a crucial role in signaling pathways which lead to cell cycle progression and cellular proliferation. The Food and Drug Administration ...

Lannett Company announced it has received approval from the Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Letrozole Tablets, the generic version of Novartis‘ ...

Letrozole is prescribed for certain types of breast cancer. It's a generic medication and is available as the brand-name drug Femara. It comes as an oral tablet. The cost of letrozole can vary, but ...

Femara (letrozole) is used to treat postmenopausal women with hormone receptor-positive breast cancer. This type of breast cancer uses the hormone estrogen as fuel. Femara reduces the amount of ...

TOKYO, January 6, 2016 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai and Novartis Pharma K.K. have agreed to terminate the agreement regarding co-marketing of aromatase ...

Co announces it has received tentative approval from the FDA for its Abbreviated New Drug Application for Letrozole Tablets U.S.P, 2.5 mg.